MX2021004864A - Formulacion basada en ciclodextrina de un inhibidor de bcl-2. - Google Patents

Formulacion basada en ciclodextrina de un inhibidor de bcl-2.

Info

Publication number
MX2021004864A
MX2021004864A MX2021004864A MX2021004864A MX2021004864A MX 2021004864 A MX2021004864 A MX 2021004864A MX 2021004864 A MX2021004864 A MX 2021004864A MX 2021004864 A MX2021004864 A MX 2021004864A MX 2021004864 A MX2021004864 A MX 2021004864A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
pharmaceutical composition
relates
bcl
inhibitor
Prior art date
Application number
MX2021004864A
Other languages
English (en)
Inventor
Maïa Chanrion
Jean-Manuel Pean
Caroline Chemin
Thu Thuy Tran
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2021004864A publication Critical patent/MX2021004864A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica que comprende 5-(5-cloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidrois oquinolin-2(1H)-il]carbonil}fenil)-N-(5-ciano-1,2-dimetil-1H-pirr ol-3-il)-N-(4-hidroxifenil)-1,2-dimetil-1H-pirrol-3-carboxamida, referida en la presente memoria como "Compuesto A", o una sal farmacéuticamente aceptable de la misma, y una ciclodextrina. Más específicamente, la invención se refiere a una composición farmacéutica sólida que comprende el Compuesto A y una ciclodextrina, y una composición farmacéutica para administración parenteral preparada disolviendo esta composición farmacéutica sólida. Además, la invención se refiere al uso de dichas composiciones para el tratamiento del cáncer.
MX2021004864A 2018-10-31 2019-10-30 Formulacion basada en ciclodextrina de un inhibidor de bcl-2. MX2021004864A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862753164P 2018-10-31 2018-10-31
PCT/EP2019/079644 WO2020089286A1 (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor

Publications (1)

Publication Number Publication Date
MX2021004864A true MX2021004864A (es) 2021-08-11

Family

ID=68536777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004864A MX2021004864A (es) 2018-10-31 2019-10-30 Formulacion basada en ciclodextrina de un inhibidor de bcl-2.

Country Status (25)

Country Link
US (1) US20210353633A1 (es)
EP (1) EP3873529A1 (es)
JP (1) JP2022506069A (es)
KR (1) KR20210102886A (es)
CN (1) CN112912108A (es)
AR (1) AR116922A1 (es)
AU (1) AU2019373373B2 (es)
BR (1) BR112021007987A2 (es)
CA (1) CA3117511A1 (es)
CL (1) CL2021001018A1 (es)
CO (1) CO2021005221A2 (es)
CR (1) CR20210210A (es)
DO (1) DOP2021000073A (es)
EA (1) EA202191144A1 (es)
GE (1) GEP20237580B (es)
IL (1) IL282688A (es)
JO (1) JOP20210079A1 (es)
MX (1) MX2021004864A (es)
NI (1) NI202100031A (es)
PE (1) PE20211738A1 (es)
PH (1) PH12021550878A1 (es)
SG (1) SG11202103965TA (es)
TW (1) TWI738100B (es)
UY (1) UY38431A (es)
WO (1) WO2020089286A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390735A (zh) 2020-07-31 2023-07-04 法国施维雅药厂 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
CA3214107A1 (en) 2021-03-24 2022-09-29 Les Laboratoires Servier New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041646A2 (en) * 1995-06-13 1996-12-27 Dyer, Alison, Margaret Pharmaceutical compositions containing lornoxicam and cyclodextrin
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
WO2014108918A2 (en) * 2013-01-08 2014-07-17 Mylan Laboratories Limited An injectable antifungal formulation
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018081830A1 (en) * 2016-10-31 2018-05-03 Oregon Health & Science University Combinations of agents to treat hematological malignancies

Also Published As

Publication number Publication date
US20210353633A1 (en) 2021-11-18
UY38431A (es) 2020-05-29
PH12021550878A1 (en) 2021-10-18
KR20210102886A (ko) 2021-08-20
IL282688A (en) 2021-06-30
DOP2021000073A (es) 2021-11-15
AU2019373373B2 (en) 2023-09-28
EA202191144A1 (ru) 2021-09-27
CA3117511A1 (en) 2020-05-07
CO2021005221A2 (es) 2021-07-19
NI202100031A (es) 2021-08-24
GEP20237580B (en) 2023-12-25
CN112912108A (zh) 2021-06-04
AR116922A1 (es) 2021-06-30
JOP20210079A1 (ar) 2023-01-30
WO2020089286A1 (en) 2020-05-07
AU2019373373A1 (en) 2021-05-20
JP2022506069A (ja) 2022-01-17
EP3873529A1 (en) 2021-09-08
TW202031295A (zh) 2020-09-01
PE20211738A1 (es) 2021-09-06
CR20210210A (es) 2021-05-25
TWI738100B (zh) 2021-09-01
SG11202103965TA (en) 2021-05-28
CL2021001018A1 (es) 2021-11-26
BR112021007987A2 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
PH12021550878A1 (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
WO2008004798A8 (en) Compounds that inhibit hif-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component
WO2008010921A3 (en) Modulators of pharmacokinetic properties of therapeutics
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
MX2009008935A (es) Moduladores de las propiedades farmacocineticas de productos terapeuticos.
JP2020097577A5 (es)
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
AU2018251118A8 (en) Pharmaceutical composition containing MOR agonist and KOR agonist, and uses thereof
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
TN2019000117A1 (en) Liposomal formulation for use in the treatment of cancer
MX2020011873A (es) Nuevos derivados de quinolina.
TW200517106A (en) Sustained release pharmaceutical compositions
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
MX2021014680A (es) Derivado de benzotriazol.
MX2022001743A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
CR20190545A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
WO2020232191A8 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
WO2013188465A3 (en) Treating drug addiction and preventing drug relapse
ZA202203106B (en) Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections
PH12021550323A1 (en) Dendrimer formulations